Evan Yu, MD
Evan Y. Yu, M.D., is a medical oncologist specializing in prostate, bladder, and testicular cancer treatment and research. He graduated Alpha Omega Alpha from the University of Washington School of Medicine and his post-doctoral training was at Harvard Medical School. He completed internal medicine residency at the Brigham and Women’s Hospital and oncology fellowship at the Dana-Farber Cancer Institute. He returned to Seattle at the end of 2004 to join the faculty at the University of Washington and Fred Hutchinson Cancer Research Center. He now is a Full Professor, and he is the director of the Clinical Trials Core for GU malignancies, as well as having an integral role in the Pacific Northwest Prostate Cancer SPORE. His research focuses on testing the next wave of novel molecular targeted therapies and immunotherapy techniques, with a complementary focus on biomarkers.
In addition to an active clinical and research practice, he also is the Medical Director for Clinical Research Support at the Fred Hutch/University of Washington Cancer Consortium. He served as a Hematology/Oncology Fellowship Program Director for a decade at the Fred Hutchinson Cancer Research Center. He has regularly been voted a “Top Doctor” by Castle Connolly, U.S. News and World Report, Seattle magazine, and Seattle Met magazine. He has served for many years on the National Cancer Institute Genitourinary Cancers Steering Committee and is now the Co-Chair for the National Cancer Institute Prostate Cancer Task Force. He remains active in SWOG and he also serves as an editor for Clinical Cancer Research and Uro-Today.
Financial relationships
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:ExelixisDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Advanced Accelerator ApplicationsDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:MerckDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:JanssenDate added:Date updated:12/22/2021